Project information
From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
- Project Identification
- MSM0021622434
- Project Period
- 1/2007 - 12/2013
- Investor / Pogramme / Project type
-
Ministry of Education, Youth and Sports of the CR
- Research Intents
- MU Faculty or unit
- Faculty of Medicine
- Keywords
- multiple myeloma; proteomics; genomics
Monoclonal gammapathies and multiple myeloma in particular are among the most common and debilitating malignancies in the elderly population. In the last decade, there have been dramatic developments in basic and applied research in the field. New treatments have become available and treatment standards have changed. Treatment results have substantially improved and the probability of 10-year survival increased from 5% to 20% in the last decade. However, the disease is still incurable. The treatment strategy today includes potentially 3-5 regimens administered over a period of 10 to 15 years. There is increased tendency to apply treatment specifically tailored for a subgroup of patients with a well-defined risk and response rate.
Publications
Total number of publications: 314
2011
-
Clonality assessment in monoclonal gammopathies
Year: 2011, type: Conference abstract
-
Clonality assessment using 8-color flow cytometry
Year: 2011, type: Conference abstract
-
Correlation of gene expression with centrosome amplification in multiple myeloma
Year: 2011, type: Conference abstract
-
Correlation of plasma cell phenotype with cytogenetic and morphological findings in multiple myeloma
Year: 2011, type: Conference abstract
-
Detection of new protein alterations in human B-lymphoblastoid cell line ARH-77 after bortezomib treatment
Year: 2011, type: Conference abstract
-
First experience with whole genome amplification for aCGH investigation of chromosomal abnormalities in MGUS patients
Year: 2011, type: Conference abstract
-
Flow cytometric analysis of CD4 and CD8 regulatory cells before and after lenalidomide plus dexamethasone treatment in multiple myeloma patients
Year: 2011, type: Conference abstract
-
Flow Cytometric Phenotyping and Analysis of T Regulatory Cells in Multiple Myeloma Patients
Klinická onkologie, year: 2011, volume: 24, edition: Suppl.
-
Flow Cytometry in Monoclonal Gammopathies
Klinická onkologie, year: 2011, volume: 24, edition: Suppl.
-
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients
Haematologica/the hematology journal, year: 2011, volume: 96, edition: 11, DOI